Ataibeckley INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ

11 Aug 2026

ATAI

10-Q: AtaiBeckley Announces Potential $6.75/Share Acquisition by Eli Lilly

AtaiBeckley Inc. has entered into a merger agreement with Eli Lilly and Company for an acquisition valued at $6.75 per share plus contingent value rights, while reporting Q2 2026 results with increased R&D expenses and continued net losses.